Travere beefs up rare kidney disease portfolio with up to $1.1B China deal

civorebrutinibFilspariPositive

AI Analysis

Summary

Travere Therapeutics secured an exclusive license to oral BTK inhibitor civorebrutinib in a deal valued at up to $1.1B, which analysts view as complementary to its IgA nephropathy treatment Filspari for rare kidney disease.

Importance:7/10

Sentiment:

0.60

licensing_dealrare_diseaseBTK_inhibitorkidney_diseaseIgA_nephropathyM&A

Related Companies

$CPHI

Read the original article

Published by BioSpace on June 3, 2026 11:24 AM

Read Original